Filing Details

Accession Number:
0001209191-21-010517
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-02-12 21:28:43
Reporting Period:
2021-02-10
Accepted Time:
2021-02-12 21:28:43
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1370053 Anaptysbio Inc ANAB () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1239648 J Eric Loumeau C/o Anaptysbio, Inc.
10421 Pacific Center Court, Suite 200
San Diego CA 92121
Coo, General Counsel No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-02-12 10,000 $14.02 10,000 No 4 M Direct
Common Stock Disposition 2021-02-12 10,000 $35.00 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Acquisiton 2021-02-10 45,000 $0.00 45,000 $29.70
Common Stock Stock Option (right to buy) Disposition 2021-02-12 10,000 $0.00 10,000 $14.02
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
45,000 2031-02-09 No 4 A Direct
88,000 2029-12-08 No 4 M Direct
Footnotes
  1. The transaction reported on this Form 4 were effected pursuant to a Rule 105b-1 trading plan adopted by the reporting person.
  2. The stock option vests and becomes exercisable as to 25% of the shares subject to the option on February 10, 2022, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.
  3. The stock option vested as to 25% of the shares subject to the option on December 6, 2020, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.
  4. In addition to the remaining option to purchase 88,000 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 147,500 shares of common stock, which options vest according to their terms.